Paul Penepent - Novartis Head Accounting
| NVSEF Stock | USD 98.25 6.75 6.43% |
Insider
Paul Penepent is Head Accounting of Novartis AG
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Laura Sayavedra | Enbridge | 57 | |
| Gordon Loh | Pfizer Inc | N/A | |
| Julie Brown | GSK plc | 61 | |
| Amie OToole | Alphabet Inc Class C | 49 | |
| Diana Conrad | GSK plc | N/A | |
| Noam Zakay | IONQ Inc | N/A | |
| V Darkes | Enbridge | 71 | |
| Fiona Cicconi | Alphabet Inc Class C | 58 | |
| Jungsang Kim | IONQ Inc | 55 | |
| William Gannon | Genprex | N/A | |
| DVM DVM | Pfizer Inc | 60 | |
| Maria Llano | Grifols SA ADR | 59 | |
| Patrick Murray | Enbridge | 48 | |
| Mayank Ashar | Enbridge | 65 | |
| Aamir Malik | Pfizer Inc | 48 | |
| Jonathan Morgan | Enbridge | N/A | |
| Guardie Banister | Enbridge | 63 | |
| Nuria Lapea | Grifols SA ADR | 60 | |
| Steven JD | Grifols SA ADR | 64 | |
| Tony Wood | GSK plc | N/A | |
| William Carapezzi | Pfizer Inc | 63 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor, Chief Sandoz | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| MarieFrance Tschudin, Pres Officer | ||
| Paul Penepent, Head Accounting | ||
| Samir MD, Global Relations | ||
| Robert PharmD, Chief Officer | ||
| Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | ||
| Karen Hale, Chief Officer | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Harry Kirsch, Chief Officer |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.